Therapeutic particles suitable for parenteral administration and methods of making and using same
View Patent ↗Disclosed herein are therapeutic compositions for treating and preventing diseases such as neointimal hyperplasia (NIH), where the compositions comprise a therapeutic particle that has a localized association with a blood vessel and a therapeutic agent, such as an anti-NIH agent. Methods of use of the therapeutic compositions are also disclosed.
1. A therapeutic particle comprising:
about 1 to about 20 mole percent PLA-PEG-basement vascular membrane targeting peptide, wherein the targeting peptide comprises PLA having a number average molecular weight of about 15 to about 20 kDa and PEG having a number average molecular weight of about 4 to about 6 kDa;
about 10 to about 25 weight percent anti-neointimal hyperplasia (NIH) agent; and
about 50 to about 90 weight percent non-targeted poly-lactic acid-PEG, wherein the therapeutic particle is capable of releasing the anti-NIH agent to a basement vascular membrane of a blood vessel for at least about 8 hours when the therapeutic particle is placed in the blood vessel.
2. The therapeutic particle of claim 1 , wherein the non-targeted poly-lactic acid-PEG has PLA with a number average molecular weight of about 20 kDa to about 25 kDa.
3. The therapeutic particle of claim 2 , wherein the basement vascular membrane targeting peptide is selected from: CREKA (SEQ ID NO: 1) or CARLYQKLN (SEQ ID NO: 2).
4. The therapeutic particle of claim 3 , wherein the anti-neointimal hyperplasia (NIH) agent is paclitaxel.